Adam M. Brufsky, MD, PhD | Authors

FARM FRESH PHARMACY

455 MERRIMAC TRL STE A

Articles

Relapsed/Refractory HER2+ Metastatic Breast Cancer

February 15, 2021

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

Bisphosphonates in Breast Cancer: A Triple Winner?

January 15, 2015

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.